UPMC Physicians and Researchers to Present at the 61st American Society of Hematology Annual Meeting & Exposition

December 2, 2019 UPMC Hillman Cancer Center and UPMC Children’s Hospital of Pittsburgh will be well-represented at the 61st American Society of Hematology Annual Meeting & Exposition (ASH) Annual Meeting from December 7-10 in Orlando, FL.

The event brings together more than 25,000 health professionals from around the globe to one location. The meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology.

Following is a list of courses, posters, and presentations to be delivered by physicians and researchers from UPMC Hillman Cancer Center and UPMC Children’s Hospital

Friday, Dec. 6

Training Program Directors’ Workshop
Implicit Bias Topic with Case Based Questions
9 a.m. to 12 p.m.
Annie Im, MD

Saturday, Dec. 7

Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Results from CAR T-Cell Trials
2 to 3:30 p.m.
Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Michael D. Jain, MD, PhD, Miriam T. Jacobs, MD, Loretta J. Nastoupil, MD, MSc, Jay Y. Spiegel, MD, FRCPC, Gao Feng, Yi Lin, MD, PhD, Matthew A. Lunning, DO, FACP, Saurabh Dahiya, MD, Lazaros J. Lekakis, MD, Patrick M. Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Andre Goy, MD, Brian T. Hill, MD, Javier Munoz, MD, Julio Chavez, Aaron P. Rapoport, Julie M. Vose, MD, MBA, David B. Miklos, MD, PhD, Sattva S. Neelapu, MD, N. Nora Bennani, MD, Charalambos Andreadis, MD, MSCE, Alison R. Sehgal, MD, Armin Ghobadi, MD and Frederick L. Locke, MD

Health Services Research—Non-Malignant Conditions: Poster I
Beliefs and Practices Among Adults with Sickle Cell Disease Regarding Reproductive Health Decisions and Family Planning
5:30 to 7:30 p.m.
Laura Ibidunni, Kristin Paulyson Nunez, MS, CGC, Jude C. Jonassaint, RN, and Laura De Castro, MD, MSc

Regional Differences in the Beliefs and Practices Among Adults with Sickle Cell Disease Regarding Reproductive Health and Family Planning: A Sub-Analysis
Laura Ibidunni, Kristin Paulyson Nunez, MS, CGC, Jude C. Jonassaint, RN, and Laura De Castro, MD, MSc

Health Services Research—Malignant Conditions (Myeloid Disease): Big Data in Studying Myeloid Malignancies
4 to 5:30 p.m.
Levofloxacin Prophylaxis Is Effective and Cost-Effective in Pediatric Patients with Acute Myeloid Leukemia Clinically Relevant Abstract
Meghan McCormick, MD, Erika Friehling, MD, Ram Kalpatthi, MD, and Ken Smith, MD, MS

Outcomes Research—Non-Malignant Conditions: Poster I
5:30 to 7:30 p.m.
Morbidity, Mortality, and Healthcare Utilization in a National Cohort of Pediatric Patients with Hemophagocytic Lymphohistiocytosis Who Received Hematopoietic Stem Cell Transplant
Archana Ramgopal, DO, Meghan McCormick, MD, Ram Kalpatthi, MD, Louis Rapkin, MD, James Zullo, and Steven William Allen, MD, BS

Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster I
5:30 to 7:30 p.m. 
Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium
Miriam T. Jacobs, MD, Michael D. Jain, MD, PhD, Jay Y. Spiegel, MD, FRCPC, Loretta J. Nastoupil, MD, MSc, Yibo Li, MD, Gao Feng, Matthew A. Lunning, DO, FACP, Lazaros J. Lekakis, MD, Saurabh Dahiya, MD, Patrick M. Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, Charalambos Andreadis, MD, MSCE, Javier Munoz, MD, Julio Chavez, N. Nora Bennani, MD, Aaron P. Rapoport, Julie M Vose, MD MBA, David B. Miklos, MD, PhD, Sattva S. Neelapu, MD, Armin Ghobadi, MD, and Frederick L. Locke, MD

Sunday, Dec. 8

CLL: Therapy, excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL
4:30 to 6 p.m. 
Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib
Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD, PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, and William G. Wierda, MD, PhD

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib
5:30 p.m.
CLL: Therapy, excluding Transplantation: BTK Inhibitors and CAR T Cells in CLL
Hematology Disease Topics & Pathways: Biological, apheresis, CRS, Diseases, Leukemia, Therapies, neurotoxicity, CLL, CAR-Ts, Adverse Events, Biological Processes, Technology and Procedures, Clinically relevant, Lymphoid Malignancies, immune mechanism, flow cytometry, NGS
Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD, PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, and William G. Wierda, MD, PhD

Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Poster II
6 to 8 p.m. 
Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD, PhD, Milos D. Miljkovic, MD, MSc, Jagan R. Muppidi, MD, PhD, Craig A. Portell, MD, Rafic Farah, MD, Seung Tae Lee, MD, PhD, Anna Marie Juanitez, RN, Lydia L. Chou, CRNP, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis Staudt, MD, Mark Roschewski, MD, and Wyndham Wilson, MD

Response-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS
Mark Roschewski, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Matthias Holdhoff, MD, PhD, Lode J. Swinnen, MB ChB, Michael Glantz, MD, PhD, Craig A. Portell, MD, Jakub Svoboda, MD, Rafic Farah, MD, Michail S. Lionakis, MD, ScD, Louis Staudt, MD, and Wyndham Wilson, MD

Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II
6 to 8 p.m. 
Trial in Progress: A Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease (GRAVITAS-309)
Annie Im, MD, Rodica Morariu-Zamfir, MD, Maureen Bleam, BS, Ying Yan, PhD, and Steven Z. Pavletic, MD, MS

Adoptive Immunotherapy: Mechanisms and New Approaches: Poster II
6 to 8 p.m. 
Anti-Leukemia Effects of NK Cell-Derived Exosomes
Michael Boyiadzis, MD, Chang Sook Hong, PhD, and Theresa L Whiteside, PhD

Acute Myeloid Leukemia: Clinical Studies: Poster II
6 to 8 p.m. 
Impact of Upfront Chemotherapy on Overall Survival in Isolated Myeloid Sarcoma Clinically Relevant Abstract
Konstantinos Lontos, MD, Jonathan G. Yabes, PhD, and Michael Boyiadzis, MD

Monday, Dec. 9

Myeloproliferative Syndromes: Clinical: Emerging and Novel Targeted Therapies
7 to 8:30 a.m.
A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis
Kristen Pettit, MD, Aaron T. Gerds, MD, MS, Abdulraheem Yacoub, MD, Justin M. Watts, MD, Maciej Tartaczuch, MD, Terrence J. Bradley, MD, Jake Shortt, MBBS FRACP FRCPA PhD, William S. Stevenson, MBBS, PhD, Natasha Joan Curtin, MD, FRACP, FRCPA, James M. Rossetti, DO, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Georges Natsoulis, PhD, Amber Jones, MA, Moshe Talpaz, MD, Jennifer Peppe, BS, David M. Ross, MD, PhD, and Hugh Young Rienhoff Jr., MD

Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)
10:30 a.m. 
Elizabeth Stenger, MD, Rachel Phelan, MD, MPH, Bronwen E. Shaw, PhD, MRCP, FRCPath, Minoo Battiwalla, MD, Stephanie Bo-Subait, MPH, Ruta Brazauskas, PhD, David K. Buchbinder, MD, MSHS, Betty K. Hamilton, MD, Shalini Shenoy, MD, and Lakshmanan Krishnamurti, MD

Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Outcomes and Late Effects
10:30 a.m. to 12 p.m. 
Excellent Overall Survival and Low Incidence of Late Effects in Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Sickle Cell Disease: A Report from the Center for International Blood and Marrow Transplant Research (CIBMTR)
Elizabeth Stenger, MD, Rachel Phelan, MD, MPH, Bronwen E. Shaw, PhD, MRCP, FRCPath, Minoo Battiwalla, MD, Stephanie Bo-Subait, MPH, Ruta Brazauskas, PhD, David K. Buchbinder, MD, MSHS, Betty K. Hamilton, MD, Shalini Shenoy, MD, and Lakshmanan Krishnamurti, MD

Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
2:45 p.m.
Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Cellular Therapies
N. Nora Bennani, MD, Matthew J. Maurer, MS, Loretta J. Nastoupil, MD, MSc, Michael D. Jain, MD, PhD, Julio C. Chavez, MD, Amanda F Cashen, MD, Saurabh Dahiya, MD, Lazaros J. Lekakis, MD, Patrick M Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, Khoan Vu, MD, Charalambos Andreadis, MD, Javier Munoz, MD, MS, FACP, Aaron P. Rapoport, Julie M Vose, MD MBA, David B Miklos, MD, PhD, Frederick L. Locke, MD, Sattva S Neelapu, MD and Yi Lin, MD, PhD

Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Retrospective/Observational Studies: Cellular Therapies
2:45 to 4:15 p.m.
Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
N. Nora Bennani, MD, Matthew J. Maurer, MS, Loretta J. Nastoupil, MD, MSc, Michael D. Jain, MD, PhD, Julio C. Chavez, MD, Amanda F. Cashen, MD, Saurabh Dahiya, MD, Lazaros J. Lekakis, MD, Patrick M. Reagan, MD, Olalekan O. Oluwole, MBBS, MPH, Joseph P. McGuirk, DO, Abhinav Deol, MD, Alison R. Sehgal, MD, Andre Goy, MD, Brian T. Hill, MD, Khoan Vu, MD, Charalambos Andreadis, MD, Javier Munoz, MD, MS, FACP, Aaron P. Rapoport, Julie M. Vose, MD MBA, David B. Miklos, MD, PhD, Frederick L. Locke, MD, Sattva S. Neelapu, MD, and Yi Lin, MD, PhD

Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster III
Program: Oral and Poster Abstracts
6 to 8 p.m. 
The Role of SOD2 in Maintaining Endothelial Cell Function in SCD
Atinuke Dosunmu-Ogunbi, Yingze Zhang, PhD, Seyed Mehdi Nouraie, PhD, MD, and Adam Straub, PhD

Note: UPMC Hillman Cancer Center, UPMC Children’s Hospital of Pittsburgh, and University of Pittsburgh presenters are indicated in bold. 

Annual Cocktail Reception

Additionally, Mounzer E. Agha, MD, Warren D. Shlomchik, MD and A. Kim Ritchey, MD will host a cocktail reception on Saturday, Dec. 7 from 7:30 to 9:30 p.m. at Hyatt Regency Orlando Rocks Lounge. 

Register for the adult and pediatric reception.